Ristoglogene autogetemcel
Gene therapy / editing
Also known as BEAM 101
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Company guidance: data expected by year-end 2026 (Beam Therapeutics Inc., 3 Nov 2026). “Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.” Source ↗
Company guidance: regulatory filing expected Year-End 2026 (Beam Therapeutics Inc., 10 Nov 2026). “Results Support Planned U.S. Biologics License Application (BLA) Submission for risto-cel, Expected as Early as Year-End 2026” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05456880 NCT05456880 · Sickle Cell Disease Registry: NCT05456880 | 1/2 | Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baseline (6 months to time of analysis as compared to baseline); Proportion of patients with successful neutrophil engraftment (BEAM-101 administration to month 24); Time to neutrophil engraftment (BEAM-101 administration to month 24); Time to platelet engraftment (BEAM-101 administration to month 24); Transplant-related mortality within 100 days after beam-101 treatment (BEAM-101 administration to day 100); Safety and tolerability assessments based on frequency, severity and seriousness of adverse events (AE's) (BEAM-101 administration through month 24) 2028-02 | No comparator arm | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Sickle Cell Disease: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ristoglogene Autogetemcel: this drug | Phase 1/2 | Gene therapy / editing | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | Partial signal | Featured results are non-efficacy only in this race | |
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | Weak signal | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Droxia) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Siklos) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Xromi) | Approved | Small molecule | Ribonucleotide reductase | Weak signal | No reviewed efficacy summary in this indication | |
| L-Glutamine (Endari) | Approved | Small molecule | Amino Acid | Reliable signal | NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15) | |
| Lovotibeglogene Autotemcel (Lyfgenia) | Approved | Gene therapy / editing | Beta-globin gene addition (betaA-T87Q) | not yet graded | No reviewed efficacy summary in this indication | |
| Etavopivat | Phase 3 | — | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Mitapivat (Pyrukynd) | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Decitabine / Tetrahydrouridine (NDec) | Phase 2 | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| ITU512 | Phase 1/2 | Small molecule | WIZ transcription factor | not yet graded | No reviewed efficacy summary in this indication | |
| Nula-Cel | Phase 1/2 | Gene or cell therapy (subtype unspecified) | HBB gene (sickle mutation correction) | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 1 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| SCD-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| VAS-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | Reliable signal | NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92 |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ristoglogene autogetemcel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
February 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent